Bio-Gene appoints MVAB Audit as new external auditor in administrative change

Bio-Gene Technology Ltd. ( (AU:BGT) ) just unveiled an announcement.

Bio-Gene Technology Limited has appointed MVAB Audit Pty Ltd as its new external auditor, effective 10 April 2026, following the incorporation of the existing audit practice and with all required regulatory consents in place. The company stressed that the change is purely administrative and structural, with no alteration to the audit engagement partner, audit team, audit scope or methodology, and that it does not arise from any audit, governance or independence concerns.

Bio-Gene indicated that shareholders will be asked to ratify the appointment of MVAB Audit Pty Ltd at the 2026 Annual General Meeting, formalising the transition within its governance framework. The move signals continuity in the company’s assurance processes while aligning its audit arrangements with the restructured audit practice, limiting operational disruption for stakeholders.

More about Bio-Gene Technology Ltd.

Bio-Gene Technology Limited is an Australian agtech company developing novel bio-insecticides designed to tackle global insecticide resistance and growing demand for natural pest control solutions. Its products, including proprietary technologies such as Flavocide and Qcide, target applications in crop protection, grain storage, public health, animal health and consumer markets, aiming to deliver effective pest management with minimal impact on human health and the environment.

Average Trading Volume: 132,980

Technical Sentiment Signal: Sell

Current Market Cap: A$9.46M

For a thorough assessment of BGT stock, go to TipRanks’ Stock Analysis page.